Health Canada Approves XEOMIN® (incobotulinumtoxinA) for Treatment of Adults with Post-stroke Lower Limb Spasticity in the Ankle and Foot
Merz Therapeutics, a business of Merz Group and a leader in the field of neurotoxins, today announced that Health Canada approved XEOMIN® (incobotulinumtoxinA) for the treatment of post-stroke lower ...
Pharmabiz10d
Merz Therapeutics gets Health Canada approval for Xeomin to treat adults with post-stroke lower limb spasticity in the ankle and foot
Merz Therapeutics, a business of Merz Group and a leader in the field of neurotoxins, announced that Health Canada approved Xeomin (incobotulinumtoxinA) for the treatment of post-stroke lower limb ...